BF
Deep Genomics is an AI-driven drug discovery company developing RNA therapeutics for genetic diseases. Its proprietary AI Workbench platform makes billions of predictions across the human genome to identify and design oligonucleotide therapeutics targeting previously undruggable diseases.
Deep Genomics is an AI-driven drug discovery company developing RNA therapeutics for genetic diseases. Its proprietary AI Workbench platform makes billions of predictions across the human genome to identify and design oligonucleotide therapeutics targeting previously undruggable diseases.
Spun out in 2015 from the University of Toronto by machine-learning researcher Brendan Frey with co-founders Andrew Delong, Hannes Bretschneider, and Hui Yuan Xiong. The team had pioneered applying deep learning to genomic prediction; Deep Genomics commercialized that science to design RNA therapeutics for genetic diseases.
O'Callaghan won gold at the second annual Stevie Awards for Technology Excellence in August 2025, highlighting the company's growth as an AI-first TechBio organization.
Two highly regarded scientific leaders join the SAB as Deep Genomics advances its BigRNA AI foundation model platform for RNA therapeutics discovery.
Expansion into the Cambridge biotech hub supports the company's clinical development ambitions, following its Series C financing and BioMarin partnership.
SoftBank Vision Fund 2 led a $180M Series C to advance AI-designed programmable RNA therapeutics; CPPIB, Fidelity and Alexandria participated.
Future Ventures led a $40M Series B financing round to expand the AI Workbench platform for genetic-disease drug discovery.
Co-Founder
University of Toronto
Co-founder of Deep Genomics, contributing machine-learning research applied to genomic prediction.
Co-Founder
University of Toronto
Co-founder of Deep Genomics; contributed deep-learning approaches to genomic variant interpretation.
Co-Founder
University of Toronto
Co-founder of Deep Genomics; researcher applying machine learning to genomic biology.
$233M raised total
No H1B sponsorship data available for this company.